Sera Prognostics
Sera Prognostics is a US women's-health diagnostics company commercializing blood-based biomarker tests that assess preterm birth risk during pregnancy.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sera Prognostics is an American molecular diagnostics company focused on women's health, specifically pregnancy and the prediction of preterm birth. It develops blood-based biomarker tests that combine protein measurements with clinical risk factors to estimate a pregnant patient's likelihood of delivering prematurely, aiming to help clinicians target monitoring and interventions earlier than standard care allows. The company's best-known offering is the PreTRM test, a commercially available blood test for early assessment of preterm birth risk in singleton pregnancies. Sera positions itself at the intersection of diagnostics, obstetrics and health economics: preterm birth is a major driver of neonatal morbidity, mortality and healthcare cost, and the company argues that earlier risk stratification can improve outcomes and reduce spending across the pregnancy episode of care. Sera Prognostics is a publicly traded company listed on Nasdaq under the ticker SERA, having completed an initial public offering in 2021. It operates as a research- and laboratory-driven business, generating revenue from test adoption by clinicians, health systems and payers, while investing heavily in clinical validation studies and reimbursement work. Its headquarters are in Salt Lake City, Utah. As a small-cap diagnostics firm, Sera's commercial story centers on evidence generation, payer coverage decisions and guideline acceptance for biomarker-based preterm birth risk assessment — a category that remains contested among obstetric professional bodies. The brand is therefore associated less with mass consumer marketing than with clinical evidence, laboratory science and women's-health innovation.
History
Sera Prognostics was founded in 2008 as a molecular diagnostics venture built around the idea that proteomic and biomarker signals in maternal blood could reveal pregnancy complications — above all, spontaneous preterm birth — well before clinical symptoms appear. The company emerged from the broader wave of interest in proteomics-driven diagnostics and established its laboratory and corporate base in Salt Lake City, Utah. Its central scientific proposition was that measuring a panel of proteins together with clinical risk factors could produce a risk score more informative than obstetric history alone. That work led to the PreTRM test, a blood test intended for use in the late first or early second trimester of singleton pregnancies, which became the company's commercial flagship. Sera invested substantially in clinical validation, including large prospective studies designed to demonstrate that its risk assessment could identify women who would deliver prematurely and, in later work, that test-guided care could reduce neonatal morbidity and length of hospital stay. These studies underpinned the company's regulatory and reimbursement strategy and its dialogue with payers. In 2021 Sera Prognostics became a publicly traded company, listing on Nasdaq under the ticker SERA. Public ownership gave it capital to expand commercial operations, pursue payer coverage and continue clinical research, but also exposed it to the scrutiny that accompanies small-cap diagnostics: investor attention to reimbursement timelines, test volumes and the outcome of clinical trials. The company has continued to position itself within the women's-health diagnostics space, emphasizing preterm birth as a major unmet need and arguing for broader adoption of biomarker-based risk stratification in routine prenatal care. Its trajectory reflects the challenges of commercializing novel pregnancy diagnostics: strong clinical rationale, but a long path through evidence generation, professional-society acceptance and payer coverage.
- 2021
Initial public offering; shares begin trading on Nasdaq under ticker SERA.
- 2008
Sera Prognostics founded as a women's-health molecular diagnostics company.
Development and commercialization of the PreTRM blood test for preterm birth risk assessment.
Products and positioning
Clinical-stage-to-commercial women's-health diagnostics brand focused on biomarker-based preterm birth risk prediction and pregnancy care optimization.
PreTRM test
Blood-based biomarker test that estimates a pregnant patient's risk of spontaneous preterm birth, used to guide prenatal monitoring and intervention.
Recent events
Sera Prognostics announces planned third-quarter fiscal 2026 results release[2]
Reported:
Sera Prognostics announced that it will report its third-quarter fiscal 2026 financial results on November 4, 2026, after market close, and host a corresponding conference call and live webcast.
Sera Prognostics appoints Scott Gleason as Chief Financial Officer[3]
Reported:
Sera Prognostics announced that Scott Gleason has been appointed Chief Financial Officer, effective August 31, 2026. Austin Aerts, CFO since June 2023, will transition to an advisory role focused on strategic initiatives and continuity.
Sera announces Medicare payment rate for PreTRM[4]
Reported:
Sera Prognostics announced that CMS had set a Medicare payment rate of $750 for the existing code covering its PreTRM test. The rate was scheduled to take effect on January 1, 2022, and the announcement stated that the rate did not necessarily mean the test would be covered by Medicare or another payer.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sera-prognostics · Editorial policy · How profiles are compiled